Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More

Systemic risk in Indian banks remains high due to COVID-19 second wave: S&P

S&P said the balance sheet weakness in smaller businesses is likely to contribute to incremental non-performing loans (NPLs) for Indian banks.

April 12, 2021 / 10:54 PM IST

S&P Global Ratings on Monday said systemic risk in Indian banks is likely to remain high in the wake of the second wave of COVID-19 and high proportion of weak loans.

S&P estimates the weak loans in banks at 11-12 percent of gross loans.

"We forecast credit losses will decline to 2.2 percent of total loans in the year ending March 31, 2022, and 1.8 percent in fiscal 2023, after staying elevated at an average of 2.8 percent in fiscals 2016-2021," S&P added.

S&P Global Ratings believes systemic risks facing banks in India is likely to remain high in the wake of the second wave of COVID-19 infections and a high proportion of weak loans.

This is even though India's economic recovery and steps by the central bank and the government to cushion the effects of the economic crisis will continue to limit stress on the balance sheets of these banks.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

S&P said the balance sheet weakness in smaller businesses is likely to contribute to incremental non-performing loans (NPLs) for Indian banks. Service sectors such as airlines, hotels, malls, multiplexes, restaurants, and retail have seen a significant loss of revenue and profit on account of COVID-19 containment measures.

Meanwhile, retail loans, especially unsecured personal loans and credit card loans, could also contribute to higher NPLs.

The government's emergency credit guarantee scheme for new loans to small and midsize enterprises (SMEs) has supported liquidity for these cash-strapped entities. However, the solvency of SMEs is unlikely be restored entirely, S&P added.

In March 2021, the government extended the period for availing the credit guarantee scheme to June 2021, and widened its scope. This would reduce stress on banks' balance sheets.

"We expect good growth prospects for the Indian economy over the next couple of years. The economy has recovered briskly over the past several months, the US based agency said.

S&P forecasts growth of 11 percent for fiscal 2022, followed by a 6.1-6.3 percent increase for next couple of years.

The control of COVID-19 remains a key risk for the economy. New infections have spiked in recent weeks and the country is in the middle of a second pandemic wave.

Some targeted lockdowns have already been implemented and more will likely be needed. The impact of broader lockdowns on the economy could be substantial, depending on their length and scope, it added.

"We believe the speed of India's vaccination rollout will be critical in mitigating the risk of future epidemic waves. India has one of the highest doses administered globally, at about 104 million. However, given the country's large population, this is only about seven doses per 100 people, considerably lower than the per capita rate of vaccination among the leading countries in this regard," S&P added.

In our view, vaccinating a much larger proportion of the population to achieve enduring herd immunity will be vital for India's growth prospects. Meanwhile, the country's strong domestic vaccine production capacity should help alleviate supply constraints over the coming months, it noted.
first published: Apr 12, 2021 10:36 pm

stay updated

Get Daily News on your Browser